Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07400107 · ClinicalTrials.gov registry record · Phase 3
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Not yet
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
NCT07400107 is a Phase 3 study that has not yet begun recruiting, run by Novo Nordisk A/S. The registered enrollment target is 1,000 participants.
The verdict
NCT07400107, a Phase 3 study, has not yet begun recruiting, sponsored by Novo Nordisk A/S.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. Participant will receive 2 injections every week: an active medicine and a placebo, both taken as injections under the skin once a week. The placebo is a treatment with no active medicine in it and will be given to all participants. In addition to placebo, participants will receive either of the active medicine NNC0487-0111 (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator). Which treatment participants get is decided by chance.
Interventions
- DRUG Semaglutide
- DRUG NNC0487-0111
- DRUG Placebo (matched to NNC0487-0111)
- DRUG Placebo (matched to semaglutide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2026-05-20 |
| Est. Completion | 2029-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07400107
The ClinicalTrials.gov registry entry for NCT07400107 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Semaglutide is the first listed.
NCT07400107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07400107 about?
NCT07400107 is a clinical study titled "AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight". The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. Participant will receive 2 injections every week: an active medicine and a placebo, both taken as injections under the skin once a week. The pl...
What is the current status of trial NCT07400107?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2026-05-20. Estimated completion is 2029-01-26.
What interventions are being tested in trial NCT07400107?
The interventions under investigation include: Semaglutide (DRUG), NNC0487-0111 (DRUG), Placebo (matched to NNC0487-0111) (DRUG), Placebo (matched to semaglutide) (DRUG).
Who is sponsoring clinical trial NCT07400107?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.